GPR52-MODULATORVERBINDUNGEN

European patent · EP4055016 · In force

Register entry

Publication number
EP4055016
Application number
EP20804658
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Nov 9, 2020
Published
Sep 14, 2022
Granted
Apr 29, 2026
Protection ends at the latest
Nov 8, 2040
Next annual fee due
Nov 30, 2026
IPC classes
C07D 471/04 (2006.01)
C07D 487/04 (2006.01)
C07D 498/04 (2006.01)
A61P 25/18 (2006.01)
A61K 31/437 (2006.01)
Priority
GB 201916298 08.11.2019
GB 201918974 20.12.2019
GB 201918992 20.12.2019
PCT application
PCT/GB2020/052832 09.11.2020
PCT publication
WO2021/090030 14.05.2021
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. May 5, 2026

    Agent entered

    Representative
    BOVARD AG, Optingenstrasse 16, 3013 Bern

    Published in Swissreg on 05.05.2026

  2. Apr 29, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 29.04.2026

Parties

Holder

Nxera Pharma UK Limited

Granta Park Great Abington, Cambridge, Cambridgeshire CB21 6DG, GB

Agent

Bovard AG

BOVARD AG

Optingenstrasse 16, 3013 Bern

Inventor

BUCKNELL, Sarah Joanne

Cambridge Cambridgeshire CB21 6DG, GB

WATSON, Stephen Paul

Cambridge Cambridgeshire CB21 6DG, GB

O'BRIEN, Michael Alistair

Cambridge Cambridgeshire CB21 6DG, GB

DE GRAAF, Chris

Cambridge Cambridgeshire CB21 6DG, GB

SWAIN, Nigel Alan

Cambridge Cambridgeshire CB21 6DG, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.